Press coverage about ViewRay (NASDAQ:VRAY) has been trending somewhat positive on Saturday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ViewRay earned a news impact score of 0.06 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.3057315146192 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

Several equities research analysts have weighed in on VRAY shares. ValuEngine cut ViewRay from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Aegis reiterated a “buy” rating and issued a $11.00 price objective on shares of ViewRay in a report on Tuesday, May 16th. Northland Securities reiterated a “buy” rating and issued a $7.00 price objective on shares of ViewRay in a report on Tuesday, May 16th. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of ViewRay in a research note on Wednesday, May 17th. Finally, Cantor Fitzgerald assumed coverage on ViewRay in a research note on Thursday, June 29th. They issued an “overweight” rating and a $10.00 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $9.50.

ViewRay (NASDAQ:VRAY) traded up 0.19% on Friday, hitting $5.30. The stock had a trading volume of 405,244 shares. ViewRay has a 1-year low of $2.64 and a 1-year high of $10.39. The firm’s market capitalization is $312.74 million. The stock’s 50-day moving average is $5.65 and its 200 day moving average is $6.25.

ViewRay (NASDAQ:VRAY) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.02. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. During the same period in the previous year, the company posted ($0.32) EPS. The company’s revenue was up 133.3% on a year-over-year basis. On average, equities research analysts predict that ViewRay will post ($0.81) earnings per share for the current fiscal year.

WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at

ViewRay Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with's FREE daily email newsletter.